Prelude Therapeutics (NASDAQ:PRLD) just reported results for the second quarter of 2024.
- Prelude Therapeutics reported earnings per share of -46 cents. This was below the analyst estimate for EPS of -42 cents.
- The company did not report any revenue for the quarter.